Adrienne Morgan

TL;DR: Investigating factors associated with non-adherence and inform the development of interventions to support women and promote adherence to adjuvant endocrine therapy following breast cancer finds distinct differences between intentional and unintentional non- adherence.

TL;DR: The Optimal Personalised Treatment of early breast cancer usIng Multiparameter Analysis preliminary study (OPTIMA prelim) is the feasibility phase of a randomised controlled trial (RCT) designed to validate the use of multiparameter assay directed chemotherapy decisions in the NHS.

TL;DR: The OPTIMA trial, which has just opened to recruitment in the UK, is the latest addition to trials in this area, and is the first to focus on the relative cost-effectiveness of alternate predictive assays.

TL;DR: To use economic analysis before a large-scale clinical trial of molecular testing to confirm the value of the trial and help prioritize between candidate tests as randomized comparators, and value of information analysis determined the most efficient publicly funded ongoing trial design in the United Kingdom.

TL;DR: The authors explored factors that influence adherence and non-adherence to adjuvant endocrine therapy (AET) following breast cancer to inform the development of supportive interventions, and found that adherence to AET is suboptimal.